ライフサイエンスコーパス: death from any cause

1 Death from any cause or hospitalization for cardiovascular ca

2 Death from any cause was not improved by RT in any subtype.

3 ; p<0.0001), heart failure (0.65 [0.50-0.85]; p=0.002), and death from any cause (0.71 [0.61-0.83]; p<0.0001).

4 from colorectal cancer (aHR = 0.72, 95% CI: 0.65, 0.79) and death from any cause (aHR = 0.72, 95% CI: 0.67, 0.76).

5 cific death (multivariable HR, 0.63; 95% CI, 0.44-0.89) and death from any cause (multivariable HR, 0.71; 95% CI, 0.60-0.

6 vascular death or HF hospitalization and its components and death from any cause.

7 rates of fatal and nonfatal major cardiovascular events and death from any cause.

8 defined as the difference in time between randomisation and death from any cause or the censor date) in the intention-to-

9 e of myocardial infarction, coronary revascularization, and death from any cause.

10 outcome of major adverse cardiovascular events, defined as death from any cause, repeat revascularization (CABG or percu

11 sentinel outcomes per 10,000 person-years were as follows: death from any cause, -31.4 (95% confidence interval [CI], -5

12 -years among patients with type 2 diabetes were as follows: death from any cause, -69.6 (95% CI, -95.9 to -43.2); death f

13 sks of anoxic brain damage or nursing home admission and of death from any cause among patients who survived to day 30 af

14 with risks of brain damage or nursing home admission and of death from any cause that were significantly lower than those

15 The primary end point was a composite of death from any cause or disabling stroke at 24 months in pati

16 The primary efficacy endpoint was composite of death from any cause or first event for worsening HF.

17 The primary endpoint was the composite of death from any cause, all strokes, and incidence of moderate

18 The primary end point was a composite of death from any cause, myocardial infarction, or major bleedin

19 PCI for myocardial infarction, the rate of the composite of death from any cause, myocardial infarction, or major bleedin

20 The primary end point was the rate of a composite of death from any cause, nonfatal myocardial infarction, or unpl

21 The primary end point was a composite of death from any cause, nonfatal myocardial infarction, revascu

22 or secondary end points included the rate of a composite of death from any cause, stroke, or myocardial infarction at 30

23 uring primary PCI failed to reduce the composite outcome of death from any cause and hospitalization for heart failure in

24 a liberal strategy with respect to the composite outcome of death from any cause, myocardial infarction, stroke, or new-o

25 The primary end point of death from any cause within 1 year after randomization occurr

26 The rate of death from any cause was lower in the liraglutide group (381

27 In those countries, diabetes less than doubles the rate of death from any cause.

28 diagnosis was significantly associated with reduced risk of death from any cause (adjusted relative risk [RR], 0.67; 95%

29 ce interval [CI], 0.47 to 0.82), as well as a lower risk of death from any cause (hazard ratio, 0.70; 95% CI, 0.50 to 0.9

30 )D3 concentrations were also associated with higher risk of death from any cause among HNC cases.

31 use after diagnosis was not associated with reduced risk of death from any cause or from cancer for patients whose tumors

32 tin use after diagnosis was associated with reduced risk of death from any cause or from cancer for patients whose tumors

33 of colon cancer, we associated statin with reduced risk of death from any cause or from cancer.

34 10 years (20% v 6%; P = .008), but had no effect on BCD or death from any cause.

35 urgery or radiotherapy because of disease deterioration, or death from any cause, assessed in the intention-to-treat popu

36 int was time to progression (time of progressive disease or death from any cause), with intention-to-treat analysis.

37 me from randomisation to biochemical or clinical failure or death from any cause) from published trial reports or present

38 (clinical or radiological progressive disease, relapse, or death from any cause).

39 ent groups for the secondary three-point composite outcome, death from any cause, cardiovascular death, fatal or non-fata

40 th, non-fatal myocardial infarction, and non-fatal stroke), death from any cause, cardiovascular death, fatal or non-fata

41 overall survival (defined as the time from randomisation to death from any cause).

42 l (defined as the time from the date of randomisation until death from any cause before data cutoff); a significant diffe

43 bisphosphonates on survival (time from randomisation until death from any cause) and failure-free survival (time from ra

44 rall survival (defined as the time from randomisation until death from any cause), analysed in the intention-to-treat pop

45 overall survival, defined as time from randomisation until death from any cause, analysed by modified intention-to-treat

46 all survival, measured as the time from randomisation until death from any cause, and assessed in the intention-to-treat

47 The primary composite outcome was death from any cause, myocardial infarction, stroke, or new-o

48 The primary outcome was death from any cause.

49 The primary end point was death from any cause or disabling stroke at 2 years.

50 The two primary 5-year outcomes were death from any cause and a composite outcome of major adverse